MedTrace Logo

Early Diagnosis as Strategy in Reducing the Incidence of Contrast-induced Nephropathy

NCT04225013 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2024-09-25

No results posted yet for this study

Summary

Renal damage due to contrast media (CM) administration is one of the main complications of cardiac intervention and is called contrast-induced nephropathy (CIN). Patients suffering from CIN have a high probability of developing acute renal failure. Today there is no treatment capable of reversing kidney damage, so the best strategy is prevention, by early diagnosis. In this regard, a line of research is currently being carried out focused on the identification of new markers capable of detecting susceptibility/predisposition to renal damage before the administration of a potentially nephrotoxic drug, even at doses that alone should not produce Kidney damage. This concept has been called predisposition to kidney damage.

Taking into account all of the above, the objective of this work is to evaluate the ability of the new markers (previously identified in preclinical models) to detect the predisposition to the CIN before administering the CM.

Conditions

  • Kidney Injury
  • Contrast-induced Nephropathy

Interventions

DIAGNOSTIC_TEST

Early kidney damage biomarkers

In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured

DIAGNOSTIC_TEST

Predisposition to kidney injury biomarkers

In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured

Sponsors & Collaborators

  • Instituto de Investigación Biomédica de Salamanca

    collaborator OTHER

  • Salamanca University Hospital

    collaborator OTHER

  • University of Salamanca

    collaborator OTHER

  • R. Laura Vicente Vicente

    lead OTHER

Principal Investigators

  • Ana Isabel Morales Martín, PhD · University of Salamanca

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-01
Primary Completion
2018-06-01
Completion
2018-06-01

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04225013 on ClinicalTrials.gov